J
Junhe League
Recombinant protein drug developer
At a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 26.7/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotechnology, Drug Development, Biotech and Pharma, Hard Tech, proteomics, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Sep 2024 | $28M | $110M | Oriza Holdings · SoYoung Technology · SDIC Unity Capital · Hongsheng Investment Management | ↗ |
| SERIES AOther financing | Oct 2022 | $28M | $110M | Zhonghe Oppo · Focus Fund · Guangdian Capital · Tonghua SDIC | ↗ |
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Junhe League in the Hangzhou ecosystem
The Junhe League office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A9 investors entered at this stage
- ZOZhonghe Oppo
- FFFocus Fund
Guangdian Capital- TSTonghua SDIC
- HCHongshi Capital
SDIC Unity Capital
Oriza Holdings
SoYoung Technology- HMHongsheng Investment Management
Source: Dealroom Talent Intelligence.
Global footprint
See Junhe League’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








